Significant Reduction of Vitreous Opacity Areas in 77% of Patients
Since 2013, substantial scientific research has evaluated the effectiveness of micronutrient supplementation in managing eye floaters.
The most recent Floater Intervention Study (FLIES) stands out as particularly significant. Not only did it show improvements in subjective visual disturbance scores and improved visual function, but researchers also utilized the ultra-widefield imaging module of the SPECTRALIS HRA + OCT from Heidelberg Engineering GmbH to capture a 30-second, 102° field, cross-polarized infrared reflectance video of the vitreous. From this video, five still images of eye floaters were extracted, making the areas of vitreous opacities visible. After 6 months, objective improvement of eye floaters was proven in 77% of patients.
Complete the form to receive the study data via email, or explore this page to discover everything about the tested micronutrient VitroCap®N—its mechanism of action, clinical feedback, and instructions for ordering samples or stocking it in practice shops, and more.
FLIES Floater Intervention Study
Submit the form to receive the Floater Intervention Study materials by email.
Understanding VitroCap®N: The Evidence-Based Micronutrient Complex
Since 2013, significant scientific research has been conducted to evaluate the efficacy of supplementation with specific micronutrients in managing eye floaters. Five clinical trials conducted by European researchers demonstrated notable improvements in patients suffering from vitreous floaters when supplemented with VitroCap®N. This food supplement contains 5 mg of zinc, 40 mg of vitamin C, 26.3 mg grape seed extract (25 mg of proanthocyanidins), 100 mg of citrus fruit extract (60 mg of bioflavonoids as Hesperidin) and 125 mg of L-lysine.
Eye care professionals who wish to receive free product samples and informational materials to provide their patients with comprehensive and straightforward advice, and offer them an evidence-based option, can order them here.
VitroCap®N
Mechanism of Action
The vitreous body has a unique protective mechanism against oxidative stress and collagen glycation. However, this mechanism loses efficacy during degeneration. Providing the eye with naturally occurring micronutrients can help reactivate this mechanism, minimising or even preventing collagen fibres from clumping. The healthy vitreous exhibits notably high concentrations of micronutrients, including:
- Vitamin C helps counter intraocular oxidative stress by consuming reactive oxygen species and free radicals in an ascorbate-dependent manner.
- Zinc stimulates the synthesis of metallothionein, a metal-binding protein that protects tissues from glycoxidation, thus exhibiting antioxidative and antiglycation properties. Zinc is also an important cofactor of superoxide dismutase 3 (SOD3), a metalloprotein enzyme that catalyses the dismutation of superoxide radicals to hydrogen peroxide and molecular oxygen. Therefore, zinc also functions to regulate oxidative stress in the vitreous.
- L-lysine, an essential free amino acid, helps prevent collagen glycation and serves as a chemical chaperone.
Other micronutrients are known to effectively combat oxidative stress and protein glycation:
- Proanthocyanidins found in grapes have been shown to inhibit protein glycation.
- Hesperidin regulates oxidative stress and reduces the level of inflammatory cytokines by inhibiting the formation of advanced glycation end products, which in turn reduces the glycation of collagen.
Incorporating these micronutrients through supplementation with VitroCap®N may potentially slow down or even reverse, the progression of floaters. The effectiveness of this approach has been demonstrated in five clinical trials.
Did you know that eye care professionals can request free samples of VitroCap®N here?
How to Objectively Prove the Reduction of Eye Floaters
In the Floater Intervention Study (FLIES), researchers used the ultra-widefield imaging module of the SPECTRALIS HRA + OCT from Heidelberg Engineering GmbH to capture a 30-second, 102° field, cross-polarised infrared reflectance video of the vitreous. Patients were asked to move their gaze in various directions, returning to a central fixation point after each movement. From the video, five still images of eye floaters were extracted, each from a different angle.
The vitreous opacity outlines were manually delineated using a ‘freehand selection‘ tool, and the areas of opacity were calculated for each image. These individual areas were then combined to provide a total measurement, reported in square centimetres.
Did you know?
The FLIES study is the first randomised, double-blind, placebo-controlled clinical trial to assess the impact of targeted nutritional supplementation on vitreous floaters. The trial included 61 patients aged 18-79 years. After 6 months of supplementation with VitroCap®N, 77% of patients experienced a reduction in vitreous opacity areas.
Expert Opinions and Clinical Feedback
VitroCap®N has been on the market for over 10 years, with eye care professionals across Europe gathering valuable clinical experience. These experts have shared their insights, contributing to a broader understanding of the supplement’s impact. In discussions and contributions from both internationally and nationally renowned physicians and researchers, the latest findings on vitreous degeneration were explored, including its effects on visual function and quality of life.
Optometry Today Roundtable: "Can your patients benefit from vitreous management?"
See the full discussion on YouTube.
- Dr. Frank Eperjesi
- Dr. Scott Mackie
- Dr. Thomas Kaercher
- Prof. John M. Nolan
Satellite symposium: “Look at vitreous- not just through it.”
The videos from the symposium can be found here.
- Dr. Jerry Sebag
- Prof. John M. Nolan
- Prof. Hans Hoerauf
- Dr. Thomas Kaercher
- Prof. Ulrich Welge-Lüßen
Complete Study Data on VitroCap®N
Research Team | Year | Duration | Design | Success Rate | Link |
|---|---|---|---|---|---|
Ankahmah et al | 2021 | 6 months | RCT (double-blind) | 66.7% | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525826/ |
Varganova et al. | 2019 | 3 months | Case-control study | 76% | https://journals.eco-vector.com/ov/article/view/11875 |
Sobol et al. | 2018 | 3 months | Observational study | 64.7% | https://www.researchgate.net/publication/326345092 |
Marchencko et al. | 2015 | 3 months | Case-control study | 65.5% | https://ebiga-vision.com/marchencko-et-al.pdf |
Kaercher et al. | 2013 | 3 months | Observational study | 87.5% | https://ebiga-vision.com/ZPA_9-2023-eye-floater-symposium |
Medical professionals can request samples and informational material
By sending samples, ebiga-VISION aims to give you the opportunity to assess the product yourself, provide your patients with comprehensive and straightforward advice, and offer them an evidence-based option for the management of floaters.
How to Stock VitroCap®N in Practice Shops
Please contact us using our contact form. We would be happy to send you a PDF with our current prices and discount levels for practice shop owners. You can also easily reach us by phone to place an order.
Where Can Patients Purchase VitroCap®N?
Patients can order VitroCap from selected pharmacies or online retailers. It is also available for purchase through the official ebiga-VISION shop. You can send your patients the following link, or they can order directly via this page:
23,50 €
Customers who require shipping to the UK or Ireland are asked to order directly from VivaQuity Ltd. / Vision and Eyes. Please make your purchase here:
54,00 €
Customers who require shipping to the UK or Ireland are asked to order directly from VivaQuity Ltd. / Vision and Eyes. Please make your purchase here:
Ingredients
Nutritional information | Per capsule = Recommended daily intake | Percentage of reference intake per capsule* |
|---|---|---|
Zinc
| 5 mg
| 50% |
Vitamin C
| 40 mg
| 50%
|
Grape seed extract | 26,3 mg
| ** |
– of which proanthocyanidins
| 25 mg
| ** |
Citrus fruit extract | 100 mg
| ** |
– of which citrus flavonoids (hesperidin)
| 60 mg
| ** |
L-Lysine
| 125 mg
| ** |
* Percentage of the reference intake per EU Regulation 1169/2011
** no nutrient reference values available / no recommendation available in the EU
Gluten-free, lactose-free, made in Europe
Contact the Distributor
Leave a brief message and a member of ebiga-VISION will contact you as soon as possible